Information Provided By:
Fly News Breaks for July 27, 2015
PCRX
Jul 27, 2015 | 07:27 EDT
Jefferies lowered its price target for Pacira Pharmaceuticals to $72 after surveying 50 high volume prescribers of Exparel. Of those surveyed, 22% have been asked to curtail utilization within the last 6 months, almost exclusively due to cost, and 18% expect to use less Exparel over that time period, Jefferies tells investors in a research note. The firm still sees growth for the drug, but has tempered its expectations following the survey. It keeps a Buy rating on Pacira.
News For PCRX From the Last 2 Days
There are no results for your query PCRX